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Serum M30 Levels: a Potential Biomarker of Severe Liver Disease in Nonalcoholic Fatty Liver
Disease and Normal Aminotransferase Levels
To the Editor:
We congratulate Fracanzani and colleagues1 on their insightful
article identifying factors associated with severe liver disease in patients
with nonalcoholic fatty liver disease (NAFLD) and normal amino-
transferase levels. First, the authors have convincingly demonstrated
that normal alanine aminotransferase (ALT) is not a valuable criterion
to exclude patients with NAFLD from liver biopsy. More importantly,
they have shown that increased insulin resistance as assessed by the
homeostasis model assessment of insulin resistance (HOMA-IR) is a
statistically significant and independent predictor of the presence of
both nonalcoholic steatohepatitis (NASH) and severe fibrosis among
subjects with NAFLD. The authors concluded that determination of
insulin resistance in subjects with normal ALT levels may be clinically
relevant in the selection of NAFLD cases for histological assessment of
disease severity and progression.1
The field of biomarkers is an area of fast growing interest in the
setting of NAFLD. A neoepitope in cytokeratin 18, termed M30 an-
tigen, becomes available at an early caspase cleavage event during ap-
optosis and has been regarded as a biochemical marker of liver
injury.2,3 Thus, we sought to determine whether serum M30 levels
may be associated with the presence of NASH among NAFLD cases
with normal ALT levels. Eighteen patients (four males and 14 fe-
males), mean age of 51.0  7.6 years, with liver biopsy-confirmed
NAFLD and normal ALT levels ( 40 U/L) were investigated. The
diagnosis of NASH was based on the Kleiner criteria.4 M30 levels were
detected by enzyme-linked immunosorbent assay (M30 Apoptosense
ELISA kit; Peviva AB, Bromma, Sweden). Compared with patients
with NAFLD without NASH (n  12), mean serum M30 levels were
significantly raised in the six patients with normal ALT and NASH
levels (198.2  37.2 IU/L versus 80.7  19.2 IU/L, P  0.01). In
multivariate analysis, M30 levels and HOMA-IR were the only inde-
pendent predictors of the presence of NASH in patients with NAFLD
and normal ALT levels.
Besides confirming the elegant proof by Fracanzani and coworkers that
determining HOMA-IR is clinically useful for identifying patients with
NAFLD who are candidates for histological assessment of disease severity,1
our pilot results allow us to postulate that M30 levels may be an additional
good index of the presence of NASH in this patient group. Further studies
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Reply:
We thank Dr. Yilmaz et al. for comments on our article.1 The results of
the pilot study Yilmaz and colleagues conducted in patients with nonal-
coholic fatty liver disease (NAFLD) and normal alanine aminotransferase
(ALT) levels confirm our finding that the severity of insulin resistance is an
independent predictor of liver damage in these patients, and suggest that
serum levels of M30, a neoepitope of cytokeratin 18 (CK-18) released
during the early phases of apoptosis, may prove useful to discriminate
patients with nonalcoholic steatohepatitis (NASH) from those with sim-
ple steatosis. There is growing interest in evaluating apoptosis markers as
potential predictors of liver damage in NAFLD, and preliminary studies in
patients with increased ALT levels have provided encouraging results.2
Recent data showed that cytokeratin CK-18 (M65 antigen) and caspase-
cleaved CK-18 (M30 antigen), two soluble forms of extracellular cytoker-
atin 18, have both a good sensitivity and specificity, with M65 having a
higher predictive value to diagnose NASH.3 Larger prospective coopera-
tive studies are needed to test the performance of these new apoptosis
markers in discriminating patients with NASH and potentially progressive
liver disease from those with benign disease, even before severe fibrosis
ensues, and to compare these tests with other noninvasive risk scores.4
Based on the present results, and the preliminary data reported by Yilmaz,
we think that future research should evaluate the combined role of genetic,
apoptotic, and serological markers of insulin resistance in the noninvasive
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Hepatitis B Virus Viral Load and Treatment Decision
To the Editor:
Tong et al. recently described the failure of several hepatitis B virus (HBV)
treatment guidelines to identify treatment eligibility for a significant propor-
tion of 67 of their patients who went on to develop hepatocellular carcinoma
or died of liver-related complications, probably due to disease progression as a
resultof inadequateviral suppression.1 However, threeof theseguidelineswere
published2-4 prior to2006,whenthe importanceofHBVviralburdenwas less
clearly established in terms of HBV-associated disease progression.5,6 The ar-
ticle by Tong and colleagues is very timely, given that recently published
Dutch guidelines as well as the most recent algorithm by Keefe et al. still
reinforce the HBV DNA threshold for treatment initiation at 105 copies/mL
for treatment initiation for all patients,7 or for patients who are hepatitis B e
antigen(HBeAg)-positive,8 respectively.Usingahigherviral loadthresholdfor
patients who are HBeAg-positive seems questionable, given that HBeAg has
been identified as an independent risk factor for disease progression. In con-
trast, withholding treatment in patients who are HBeAg-negative with viral
load up to 19,999 IU/mL (105 copies/mL) and persistently normal alanine
aminotransferase (ALT) values seems justifiable.9
It would be interesting to learn from the authors if all patients, who pro-
gressed, would have qualified for treatment following the German guidelines
(as summarized in figure 1), which were developed following the criteria ac-
cording to the workshop of the scientific medical professional societies.10
In short, these guidelines have a hierarchical approach: (1) All patients
with evidence for advanced fibrosis are eligible for antiviral therapy with an
agent with a high genetic barrier to resistance (tenofovir or entecavir at
present) in the presence of detectable HBV DNA; if no virus is detectable,
patients should be re-evaluated every 3-6 months; (2) all patients with a
viral load 104 copies/mL would qualify for therapy if ALT is (a) 2
upper limit of normal or (b) histology shows F2 fibrosis or (c) high risk
for hepatocellular carcinoma development (male gender, age, family his-
tory, or aflatoxin exposure in the past).
If viral load is less than 104 copies/mL, patients should be re-
evaluated every 6-12 months. These guidelines for HBV DNA and
ALT thresholds apply to both HBeAg-positive and HBeAg-negative
patients. Furthermore, the incorporation of histology into the deci-
sion-making process allows for the identification of a greater propor-
tion of patients at risk of disease progression, and thus eligible to
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Fig. 1. Treatment Algorithm According to the German Treatment
Guidelines for HBV.
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Revisiting the Treatment Recommendations for Chronic Hepatitis B
To the Editor:
I read with great interest the work by Tong et al.1 on the evaluation
of current treatment recommendations based on a longitudinal cohort
of 369 chronic hepatitis B patients followed for a mean of 84 months.
Under the published guidelines, in 2003-2007, 40% to 80% of pa-
tients who developed hepatocellular carcinoma (HCC) or died of liver-
related problems did not fall into the criteria for antiviral treatment.
The authors have proposed adding low platelet count and low serum
albumin to the guidelines so that up to 100% of patients who develop
HCC or die can be identified. I have a different angle of interpretation
on the results of this study.
Low platelet count and low serum albumin are surrogate markers of
portal hypertension and hepatic dysfunction, respectively. Patients
who have these laboratory findings are likely suffering from early liver
cirrhosis. In the report by Tong et al.,1 five of nine patients who
developed HCC were diagnosed as having chronic hepatitis by histol-
ogy and therefore did not fulfill the recommended treatment criteria.
These patients probably had normal alanine aminotransferase (ALT)
and/or intermediate hepatitis B virus (HBV) DNA levels (between
10,000 and 100,000 copies/mL). This observation revealed the insuf-
ficiency of liver biopsy in determining the true liver histologic staging,
particularly when the biopsy core is not long enough.2 It would be
interesting to know the length and number of portal tracts of the liver
biopsies among patients with histologic chronic hepatitis in this report.
Furthermore, 5% to 18% of hepatitis B e antigen–negative chronic
hepatitis B patients with normal ALT (30 IU/L in men and 19
IU/L in women) might already have developed liver cirrhosis.3
In the current report,1 7 of 15 patients with cirrhosis who devel-
oped HCC could not be identified by the treatment recommenda-
tions. The reason for missing these patients was most likely their low
HBV DNA levels (lower than 10,000 copies/mL). Previous large-scale
longitudinal studies have confirmed that HBV DNA and liver cirrhosis
are independent risk factors of HCC.4,5 In other words, patients with
cirrhosis have a significant risk of developing HCC even when their
HBV DNA levels are not high. In the cohort studied by Tong et al.,1
two-thirds of the patients who had HBV DNA levels lower than
10,000 copies/mL in fact had HBV DNA levels lower than 1000
copies/mL. The number of patients with cirrhosis who had undetect-
able HBV DNA but developed HCC on subsequent follow-up was not
reported. It remains dubious whether antiviral treatment can reduce
the risk of liver-related complications in patients with cirrhosis with
very low viremia.
In summary, to improve current treatment recommendations,
high-quality liver biopsy of adequate length should be encouraged
when there is clinical suspicion of liver cirrhosis (e.g., middle-age pa-
tients with low platelet count and/or low serum albumin), regardless of
the ALT and HBV DNA levels. Antiviral treatment should be recom-
mended for all patients with cirrhosis with detectable HBV DNA in
order to maximize the possible benefit of treatment.
HENRY L. Y. CHAN
The Chinese University of Hong Kong
Hong Kong SAR, China
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Do Guidelines Preclude Hepatitis B Patients from Receiving Treatment?
To the Editor:
We read with great interest the article by Tong et al.1 in the Octo-
ber 2008 issue of HEPATOLOGY.
In this article, the authors determined whether the four published
guidelines/algorithm (European Association for the Study of the Liver,
American Association for the Study of Liver Diseases, Asian Pacific
Association for the Study of the Liver, and US Panel) on hepatitis B
treatment correctly identified for treatment patients who subsequently
developed hepatocellular carcinoma (HCC) or suffered non-HCC liv-
er-related deaths. Tong et al. retrospectively analyzed the outcome of
369 hepatitis B surface antigen (HBsAg)–positive patients followed for
a mean of 7 years, and they reported that if the criteria for antiviral
therapy stated in the current treatment guidelines/algorithm had been
used, only 20% to 60% of the patients who developed HCC and 27%
to 70% of the patients who suffered non-HCC liver-related deaths
would have been identified for antiviral therapy. The authors found
that the addition of baseline serum albumin, platelet count, and pres-
ence of basal core promoter and precore mutations would improve the
accuracy of the identification of these patients to 90% to 100%. The
authors concluded that if current guidelines were used, a significant
proportion of HBsAg-positive patients would be deprived of the pos-
sible benefits of antiviral therapy.
However, the results of this and other studies on this topic2 need to
be interpreted carefully. First, all guidelines recommend that patients
who are not initiated on treatment should continue to be monitored
and that treatment should be initiated later when the indications arise.3
In this study, the authors focused on laboratory test results at the first
visit and did not consider the option of treatment after an initial period
of observation. As the authors indicated, alanine aminotransferase
(ALT) levels fluctuated during follow-up. Thus, many of the patients
would have met treatment criteria at some point during the course of
follow-up. Second, 78.5% of the patients were Asians and likely ac-
quired hepatitis B virus (HBV) infection perinatally or during early
childhood. The mean age of the patients at recruitment was 48 years,
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indicating that most of the patients had been infected for more than 4
decades. In light of recent findings that persistently high serum HBV
DNA is a predictor of clinical outcomes and significant liver disease
may be present in patients with normal ALT, the 2007 American
Association for the Study of Liver Diseases practice guidelines recom-
mended that lower HBV DNA and ALT cutoffs be applied to patients
older than 40 years and liver biopsies be performed in patients with
HBV DNA and ALT values in the grey zone.3 Finally, the authors
assumed that had antiviral treatment been administered at presenta-
tion, all cases of HCC and liver-related mortality would have been
prevented. Clinical studies have shown that antiviral therapy is not
effective in improving survival for patients with advanced liver failure.4
Moreover, antiviral therapy decreases but does not completely prevent
the risk of HCC.5,6
We congratulate the authors for conducting this study. However,
we caution readers that decisions on hepatitis B treatment should not
be based solely on laboratory test results at the first visit. Given the
fluctuating nature of chronic HBV infection, all patients should be
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Reply:
We thank Tilmann et al.,1 Chan,2 and Degertekin and Lok3 for
their thoughtful comments and questions concerning our article.4 As
they clearly point out, the decision to treat a patient with chronic
hepatitis B according to guidelines remains controversial, and ulti-
mately, the final choice to treat an individual patient should be based
on inclusion in the guideline criteria along with the clinical judgment
of the physician. As many of the guideline criteria are now being
reevaluated, the letters by Chan and Tilmann et al. aptly raise the
question of lowering the hepatitis B virus (HBV) DNA criteria in
patients with cirrhosis to allow treatment in those patients who have
detectable HBV DNA concentrations of 104 copies/mL. The clinical
outcomes of the 129 patients with cirrhosis in our database by quali-
tative HBV DNA categories (negative, 104, and 104) are shown in
Table 1. As shown in the table, six patients with cirrhosis who either
died from a non–hepatocellular carcinoma (HCC) liver-related event
or who developed HCC had detectable baseline HBV DNA concen-
trations that were 104 copies/mL. However, 11 patients had HBV
DNA levels below the limit of detection and either died from a liver-
related event or developed HCC. Thus, modification of the treatment
guidelines to include patients who have detectable baseline HBV DNA
concentrations of 104 copies/mL would have captured patients from
our database who ultimately had a poor outcome but would not have
addressed those patients who presented with HBV DNA concentra-
tions below the limit of detection. It is important to note, as the three
letters point out and as we mentioned in the discussion section of our
original article, that further prospective treatments trials are required
to determine if antiviral therapies will have any impact on the inci-
dence of HCC, especially in patients with less active liver disease [i.e.,
low or undetectable levels of viremia and normal or nearly normal
alanine aminotransferase (ALT) levels].
The letter by Tilmann et al.1 also suggests that the use of more
recently developed guidelines, such as those published by Cornberg et
al.,5 may have captured additional patients with poor prognosis who
were not recommended for treatment by the original four guidelines
assessed in our article.4 To address this question, we conducted an
analysis of patients in our database using the criteria established by
Cornberg et al. The initial recommendation by Cornberg et al. is to
treat all patients with cirrhosis who have detectable HBV DNA. As
shown in Table 1, use of these criteria would have captured the six
patients who had a poor outcome and presented with baseline HBV
DNA levels of 104 but would have excluded the 11 patients with a
poor prognosis who presented with HBV DNA levels below the de-
tectable limits. Although we agree that the utility of treatment of
patients with cirrhosis and serum HBV DNA levels below the detect-
able limits remains unknown, it is important to point out that patients
who have serum HBV DNA levels below the detectable limit of the
assay still may have underlying HBV DNA replication at low levels and
may benefit from antiviral therapy.
The application of Cornberg et al.’s criteria5 to the population of
patients without cirrhosis in our database would have captured the
nine patients who developed HCC and were not identified by the
original European Association for the Study of the Liver, US Panel,
Asian Pacific Panel, or American Association for the Study of Liver
Diseases guidelines as candidates for therapy. In our database,4 nine
patients without cirrhosis who were excluded from antiviral therapy by
at least one of the guidelines eventually developed HCC. Cornberg et
al.’s criteria initially assess patients without cirrhosis by baseline serum
HBV DNA concentrations and recommend therapy in those patients
who have serum HBV DNA concentrations of 104 copies/mL and
who also meet subsequent ALT, liver histology, and HCC risk factor
criteria. All nine patients who were noncirrhotic and developed HCC
and who were excluded from treatment by at least one guideline had a
baseline serum HBV DNA concentration of 104 copies/mL. Of the
Table 1. Distribution of Clinical Outcomes by the HBV DNA











Negative 21 (16.3) 6 (16.2) 5 (23.8) 10 (14)
104 12 (9.3) 4 (10.8) 2 (9.5) 6 (8.5)
104 96 (74.4) 27 (73) 14 (66.7) 55 (77.5)
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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nine, only two met Cornberg et al.’s criteria for ALT cutoff (2 times
the upper limit of normal). The remaining seven patients were recom-
mended for treatment on the basis of Cornberg et al.’s guidelines as
they met the requirement for HCC risk factors (all were male and 40
years old). Thus, Cornberg et al.’s criteria captured our patients with-
out cirrhosis who were excluded from treatment by the European
Association for the Study of the Liver, US Panel, Asian Pacific Panel, or
American Association for the Study of Liver Diseases guidelines.
Finally, the letter by Degertekin and Lok3 addresses the issue of use
of serum ALT as criteria for treatment decisions. In our database, the
ALT cutoff was the most frequent reason for exclusion from treatment
by the four treatment guidelines in those patients who ultimately died
from a liver-related event or developed HCC. Degertekin and Lok
suggest that continued monitoring of ALT would have identified those
patients who were excluded from treatment on the basis of the ALT
criteria but who eventually died from a liver-related event or developed
HCC. Although we agree that continued monitoring of patients with
chronic hepatitis B would have identified some of these patients, it is
important to point out that, as shown in Fig. 1B of our original article,4
the ALT levels fluctuated significantly over time, and this makes ALT
an unreliable prognostic indicator at any time point. Additionally,
patients who did not develop liver-related complications also had fluc-
tuating ALT levels during follow-up. In contrast, the cutoffs that were
established for platelet and serum albumin concentrations (130,000
mm3 and 3.5 g/dL, respectively) were significantly more reliable
than ALT monitoring because in no case did a patient who presented
with platelet and serum albumin concentrations that met the cutoff
criteria have a subsequent value outside the range of the cutoff. There-
fore, utilization of the platelet and serum albumin concentration cut-
offs defined in our article could allow for a treatment decision to be
made earlier with less variable data in comparison with ongoing mon-
itoring of serum ALT concentrations.
At present, there are no studies that validate whether the current
treatment guidelines actually include patients who may die from liver-
related complications or develop HCC. The goals of treatment, in-
cluding hepatitis B e antigen seroconversion, normalization of ALT,
and reduced HBV DNA levels in patients who meet treatment guide-
lines, may only be a short-term fix, and continual evaluation of criteria
for including patients who develop complications must be an ongoing
process.
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The Optimal Ribavirin Dose for Patients Infected with Hepatitis C Virus Genotype 3: Should We
Utilize More?
To the Editor:
The article by Ferenci et al.1 investigating the efficacy of combina-
tion therapy with a low dose of ribavirin (RBV) in patients with
chronic hepatitis C virus (HCV) genotype 2 or 3, suggests that 400
mg/day of RBV suffices in patients infected with HCV genotype 3
(HCV-3) to achieve as high sustained virological response (SVR) rates
as those attained by the standard 800 mg/day dosing (SVR: 63.9%
versus 67.5%), whereas the same results could not be replicated in
patients with HCV-2. In the latter patients, in fact, the SVR rates
following low-dose RBV were significantly lower than those attained
with a standard dose of RBV (55.6% versus 77.8%). At variance with
the author comments, we believe that the 67% SVR rate obtained in
patients with HCV-3 by the standard-of-care RBV regimen is less than
satisfactory, too. In fact, it negatively compares with the majority of
other reports, especially studies assessing a weight-based dosing of
RBV.2-4 In fact, when the efficacy is analyzed of a 24-week treatment
with pegylated interferon-2a given at 180 g/week plus RBV at 800
mg/day in 34 consecutive patients with HCV-3 treated at our center in
the last 2 years, and the response rates are stratified by RBV dosing, a
11.5 mg/kg/day RBV dose led to higher SVR rates and lower relapse
rates, reaching statistical significance by per-protocol analysis (Table
1). Although we acknowledge that the sample size of our study was too
small to draw definite conclusions, it should be noted that the preva-









ValueN % N %
Intention-to-treat
ETR 13/14 (93) 17/20 (85) 0.67
SVR 12/14 (86) 10/20 (50) 0.06
RR 1/13 (8) 7/17 (41) 0.09
Per-protocol
ETR 13/13 (100) 17/18 (95) 1.0
SVR 12/13 (92) 10/18 (56) 0.04
RR 1/13 (8) 7/17 (41) 0.09
ETR, end of treatment response; RR, relapse rate.
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viremia 800,000 IU/mL was equally balanced between patients
given 11.5 mg/kg/day RBV and 11.5 mg/kg/day RBV (14% ver-
sus 20% and 45% versus 64%, respectively). We wonder whether body
weight–based dosing of RBV matters also in the Ferenci study, where
in fact relapsers were heavier than sustained responders (mean body
weight: 78.8 kg versus 70.4 kg). We think that a controlled study
would help understanding whether weight-based RBV can improve
the 24-week treatment outcome of patients with HCV-3 who are given
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Reply:
We thank Dr. Anghemo and his colleagues for their comments
regarding our randomized controlled trial that compared ribavirin dos-
ages of 400 and 800 mg/day in combination with peginterferon alfa-2a
given for 24 weeks in treatment-naive patients with hepatitis C virus
(HCV) genotype 2 or 3 infection.1 As Anghemo and his colleagues
correctly pointed out, no conclusions can be drawn from the few data
shown in their letter. This is also unnecessary because, in addition to
our study, two large randomized multicenter trials have compared high
and low ribavirin dosage regimens in treatment-naive genotype 2/3
patients.2,3
The seminal study by Hadziyannis et al.2 clearly showed that there
was no statistically significant difference in sustained virologic response
(SVR) rates between genotype 2/3 patients treated for 24 weeks with
peginterferon alfa-2a in combination with a high (1000 or 1200 mg/
day) or low (800 mg/day) ribavirin dosage (81% versus 84%, respec-
tively). Importantly, the incidence of treatment-related serious adverse
events, ribavirin dosage reductions, and decreases in the hemoglobin
concentration to less than 100 g/L was higher in patients randomized
to the high ribavirin dosage regimen.2
Jacobson et al.3 subsequently confirmed these results in a large
randomized multicenter trial. There was no significant difference in
SVR rates between patients treated with ribavirin at a dosage of 800 to
1400 mg/day (67.7%) or 800 mg/day (65.0%) in combination with
peginterferon alfa-2b for 24 weeks.3
Thus, our study was the third randomized multicenter study of
ribavirin dosage in genotype 2/3 patients treated for 24 weeks. Once
again, there was no significant difference in SVR rates between the two
dosage regimens. Moreover, the individual dose of ribavirin (mg/kg/
day) had no impact on SVR (Fig. 1).
On the basis of three randomized trials, we see no need to use
ribavirin doses greater than 800 mg/day in treatment-naı̈ve patients
with genotype 3, provided that the planned duration of treatment is
24 weeks.
In addition to ribavirin dose, treatment duration is a key determi-
nant of SVR. In a follow-up study, we investigated shortening the
duration of peginterferon alfa-2a treatment to 16 weeks in combina-
tion with ribavirin at a dosage of either 400 or 800 mg/day. This study
had to be stopped for ethical reasons after 100 patients had been
recruited because the relapse rate in the low-dose group was 50%. The
ACCELERATE trial subsequently demonstrated convincingly that an
abbreviated 16-week regimen of peginterferon alfa-2a plus ribavirin
800 mg/day is less effective than a 24-week regimen.4 It is not clear that
the use of higher dosages of ribavirin compensate for the inadequacy of
treatment durations less than 24 weeks.5
A small proportion of genotype 3 patients appear to be treatment-
resistant, as evidenced by detectable HCV RNA levels at week 4 of treat-
ment. These individuals have higher relapse rates and lower SVR rates
than patients who clear HCV RNA by week 4. At present, it is not possible
to identify these patients before treatment is initiated. How best to manage
these individuals is an as yet unanswered question. An ongoing random-
ized trial will determine whether prolonging treatment to 48 weeks is the
key to curing HCV infection in these individuals.
Fig. 1. Individual dose of ribavirin (mg/kg/day) versus the sustained
virologic response (SVR), relapse (REL), and nonresponse (NR) rates.
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Hepatitis B e Antigen–Negative Patients with Persistently Normal Alanine Aminotransferase Levels
and Hepatitis B Virus DNA > 2000 IU/mL
To the Editor:
We read with great interest the article by Papatheodoridis et al.
published in HEPATOLOGY.1 The authors enrolled 434 hepatitis B e
antigen (HBeAg)–negative patients and reported higher propor-
tions of histological indication for treatment (grading score  7
and/or stage  2 in Ishak’s classification) in chronic hepatitis B
patients with higher serum hepatitis B virus (HBV) DNA levels.
The authors concluded that HBeAg-negative chronic HBV patients
with increased alanine aminotransferase (ALT) and HBV DNA 
20,000 IU/mL almost always require therapeutic intervention, but
histological indications for treatment are also present in the major-
ity of such patients with HBV DNA  20,000 and even HBV
DNA  2000 IU/mL. In contrast, the majority of HBeAg-negative
patients with persistently normal alanine aminotransferase (PN-
ALT) and HBV DNA  2000 IU/mL have minimal histological
lesions, and they may not require immediate liver biopsy and treat-
ment. Some concerns have to be addressed.
First, the authors defined the 35 HBeAg-negative patients with
PNALT and HBV DNA  2000 IU/mL as inactive carriers in this
study. This is different from the diagnostic criteria for the inactive
carrier state in the practice guideline of the American Association for
the Study of Liver Diseases, which uses HBV DNA  2000 IU/mL.2
Second, the 35 patients defined as inactive carriers all had HBV DNA
levels not only 2000 IU/mL but also 20,000 IU/mL. Kumar et al.3
recently reported that in HBeAg-negative patients with PNALT, the
median (range) HBV DNA was 4.29 (2.78-9.20) log10 copies/mL;
55.3% (64/116) and 35.3% (41/116) had HBV DNA  4 and 5 log10
copies/mL, respectively. Previous studies from France4 (85 cases) and
Taiwan5 (414 cases) on HBeAg-negative patients with PNALT
showed that 18.8% and 55.8% had a level  4 log10 copies/mL, and
2.4% and 31.6% had an HBV DNA level  5 log10 copies/mL. Ac-
cordingly, 64.1%,3 12.5%,4 and 56.7%5 of HBeAg-negative patients
with PNALT and an HBV DNA level  4 log10 copies/mL had an
HBV DNA level  5 log10 copies/mL. The lack of patients with
PNALT and HBV DNA  20,000 IU/mL in the study1 raises the
concern of possible selection bias. Third, a histological indication for
treatment according to the definition of Papatheodoridis et al.1 was
present in 17% (6/35) of their inactive carriers by the presence of stage
2 fibrosis but without active necroinflammation (grading score of 2-4
in all six cases).1 Kumar et al. reported that 41.4% (24/58) of patients
with PNALT had active liver disease with significant activity (histo-
logic activity index score  3) and/or significant fibrosis (stages 2-4).
They reported that 32.4% (11/34) of patients with histologically in-
active disease and 75% (18/24) of patients with active disease had
HBV DNA  5 log10 copies/mL. In other words, 20.7% (6/29) of
patients with PNALT and HBV DNA  5 log10 copies/mL had active
liver disease.3 This implies that the histological characteristics of these
patients are a heterogeneous group. Lastly, Feld et al.6 reported in their
follow-up study that 10.7% and 20% of HBeAg-negative patients with
normal ALT and HBV DNA from 4 to 5 log10 copies/mL experienced
a rise in ALT by 6 and 12 months of follow-up, respectively. Addition-
ally, Zacharakis et al.7 reported that four (2.1%) patients who had
PNALT and serum HBV DNA levels  2000 IU/mL exhibited HBV
reactivation with increased ALT levels; there was a yearly incidence of
0.4% in their follow-up study. Considering all this, we completely
agree with the authors that HBeAg-negative patients with persistently
or transiently increased ALT and HBV DNA  20,000 IU/mL always
require therapeutic intervention, as suggested by the recommendation
of the guidelines of the American Association for the Study of Liver
Diseases,2 and we appreciate and are sympathetic to contributions
from Papatheodoridis et al. on strengthening this concept from the
histological point of view. Nevertheless, we think the conclusion that
HBeAg-negative patients with PNALT and HBV DNA  2000
IU/mL may not require immediate liver biopsy and treatment requires
a more careful reappraisal because of the limitations of the study.
HBeAg-negative patients with normal aminotransferase levels and
HBV DNA  2000 IU/mL seem to be one of the patient groups currently
overlooked in recent guidelines,2,8 so more efforts to develop strategies for
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Reply:
We thank Dr. Dai et al. for their interest in our article and for
supporting our findings that liver biopsy does not usually affect the
decision for treatment in hepatitis B e antigen (HBeAg)-negative pa-
tients with abnormal alanine aminotransferase (ALT) and hepatitis B
virus (HBV) DNA  20,000 IU/mL, although it offers valuable in-
formation for patients receiving long-term therapies. There is also no
disagreement on the need for biopsy in HBeAg-negative patients with
persistently or transiently abnormal ALT and HBV DNA  20,000
IU/mL.
The optimal management of HBeAg-negative patients with per-
sistently normal ALT (PNALT) has always been debatable. We
intentionally did not perform biopsies in such patients with HBV
DNA  2000 IU/mL, because we believe that only cases with HBV
DNA  2000 IU/mL represent a controversial group with some
likelihood of significant histological lesions. There was no selection
bias in our study because there was no patient with PNALT and
HBV DNA  20,000 IU/mL during the inclusion period. Such
patients are extremely rare in Greece.1,2 Among the last 300
HBeAg-negative PNALT patients seen at our clinics, 1% had
HBV DNA  20,000 IU/mL (200,000 IU/mL, minimal necro-
inflammation and fibrosis in both cases). We have previously com-
mented on the recent definition of “inactive carriers”,3 which does
not include PNALT patients with HBV DNA  2000 IU/mL
[however, such patients are not included under any term in recent
guidelines4,5].
Regarding the conflicting reports on histology and HBV
DNA  20,000 IU/mL in HBeAg-negative PNALT patients, we
believe that there are two main reasons. First and most important,
not all studies use the same criteria for defining PNALT (a less strict
follow-up increases the likelihood of misclassifying patients with
ALT fluctuations). We used a strict first-year follow-up with five
ALT determinations (every 3 months), while three or fewer ALT
determinations (every 6 months) were sufficient for PNALT cases
in a study from India (only two ALT values required for inclusion)6
or the United States,7 and no relevant information is provided in a
study from Taiwan.8 Second, differences in viral (e.g., genotypes)
or host genetic characteristics might be also responsible for such
discrepancies; data different from ours are reported in non-Euro-
pean studies.6-8 Inactive carriers represented 8.4% of chronic
HBV cases in the study from India,6 whereas they represent a large
proportion of chronic HBV European patients. Our data are in
agreement with another European (French) study9 including 85
PNALT patients under strict ALT follow-up; HBV DNA  20,000
IU/mL was exceptionally rare (2%), necroinflammation score was
always 6, and Ishak fibrosis score was 2 in 91% (score 3-4 in 5
of 58 cases). We also agree with Feld et al. that HBV DNA 
20,000 IU/mL is highly predictive of future ALT elevation,10 as we
have reported an increased risk of future reactivation in HBeAg-
negative PNALT patients with HBV DNA levels of even 2000
IU/mL.2
In conclusion, we believe that our findings are valid and support
the suggestion that HBeAg-negative patients with HBV DNA 
20,000 IU/mL and PNALT under strict follow-up, at least in Eu-
rope, will not benefit from liver biopsy, which is not expected to
show significant lesions. All such cases should be followed for life,
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Profiling MicroRNA Expression: a Snapshot of Nonalcoholic Steatohepatitis and a Recording of its
Pathogenesis
To the Editor:
We read with great interest the article by Cheung et al.1 In this
report, the authors analyzed the expression profile of microRNAs in
liver from patients affected by nonalcoholic steatohepatitis (NASH),
and sought to find differentially expressed microRNAs and their po-
tential role in NASH pathogenesis.
Using microarray technology, microRNA profiles of 15 subjects
with biopsy-proven NASH were normalized against 15 control sub-
jects with a normal liver histology. Out of a total of 474 microRNAs
analyzed, 46 were found differentially expressed in NASH patients. In
particular, 23 were up-regulated (i.e., miR-34a and miR-146b), while
23 were down-regulated (i.e., miR-122) and a selection of differen-
tially expressed microRNAs were further validated using quantitative
real-time polymerase chain reaction (qRT-PCR). As expected, the pre-
dicted targets of these microRNAs include proteins belonging to com-
plex intracellular pathways, which have been previously reported
altered in NASH.2 In fact, the most recognized model of NASH patho-
genesis, which is an advanced form of nonalcoholic fatty liver disease
(NAFLD), considers the elevated plasma levels of free fatty acids as a
first “hit” able to induce several secondary hits, including insulin resis-
tance, increased oxidative stress on hepatocytes, and induction of
proinflammatory cytokines.3
Interestingly, the authors demonstrated that miR-122 was signifi-
cantly decreased (63%) in patients with NASH. The in vitro silencing
of miR-122 affected the messenger RNA expression levels of predicted
targets like FAS, sterol regulatory element binding protein-1c
(SREBP-1c), SREBP-2, and 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGCR). These proteins, which play roles in the lipid
metabolism, have been already associated to NASH both in in vitro
and in vivo models.4-6
The authors conclude that human NASH is associated with unbal-
anced hepatic microRNA expression and that the alteration of lipid
metabolism, linked to miR-122 down-regulation, could contribute to
development of NASH.
Cheung’s work is a clear example of the basic application of mi-
croRNA profiling to study a pathology such as NASH. However,
although the reported results connected to miR-122 expression are
sound, their significance is difficult to interpret because the modula-
tion of this microRNA is not a specific sign of NASH. In fact, down-
regulation of miR-122 has been previously described in
hepatocarcinoma, suggesting that its function is associated with liver
cancer development.7,8
As previously underlined, we strongly believe in the power of
bioinformatics in determining the interconnections among genes,
proteins, and pathways potentially involved in NAFLD/NASH
pathogenesis.9 However, microRNA profiling and validation is
only the first step toward the comprehension of NAFLD/NASH
pathogenesis. The experimental validation of target gene (putative
targets) predictions is not an easy issue. Several software and algo-
rithms based on different rationales have been proposed in the last
several years (i.e., MiRanda, TargetScan, Diana-microT, and Pic-
Tar) to help find candidate targets regulated by microRNAs.10 Also
the performance of individual programs and their combined use to
achieve a common list of targets has been evaluated and reported.11
The development of such algorithms indeed represents a hot topic
in biomedical informatics. Moreover, the scarcity of biological data
linking specific microRNA action to the fate of their respective
messenger RNA targets so far represents the most serious limita-
tion. In fact, as correctly indicated by Cheung and colleagues, their
findings “do not provide direct proof of the involvement of mi-
croRNAs, but they serve as a broad blueprint and resource for
future hypothesis generation and hypothesis-driven studies of the
role of microRNAs in the development of NASH.”
Finally, we believe that microRNA technology could provide
not only a snapshot of the current condition of NASH, but also a
record of early pathogenetic events. Thus, a complete profiling of
microRNAs in patients with simple hepatic steatosis normalized
against NASH, or animal models that provide the possibility to
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